Targeted antibody ventures Mersana and CytomX attract venture dollars amid partnering promise

Companies on opposite US coasts announced venture capital funding on 31 July to boost next-generation targeted discovery and development platforms. Cambridge, Massachusetts-based antibody-drug conjugate (ADC) specialist Mersana Therapeutics raised $27 million in a Series A-1 round and CytomX Therapeutics in San Francisco increased its Series B round to $41 million for its tissue-specific antibodies.

Companies on opposite US coasts announced venture capital funding on 31 July to boost next-generation targeted discovery and development platforms. Cambridge, Massachusetts-based antibody-drug conjugate (ADC) specialist Mersana Therapeutics raised $27 million in a Series A-1 round and CytomX Therapeutics in San Francisco increased its Series B round to $41 million for its tissue-specific antibodies.

The investments in both companies indicate the venture capital interest in platforms that make prime partnership candidates for pharmaceutical companies...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category